The intern will generate DNA sequences to make modified verotoxin proteins that will effectively disrupt the breakdown of a mutant protein (the CFTR protein) that is found in patients with cystic fibrosis. The mutant CFTR protein has normal function but is degraded in cystic fibrosis individuals because of the mutation. The modified verotoxin will reduce […]

The intern will use screening methods to define which gene which are altered in the Jurkat human T cell line following incubation with the Verotoxin B subunit as a means to define the potential mechanism by which this treatment protects these cells from HIV1 infection in vitro. LISI Therapeutics will benefit by increasing their license […]